Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 17/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482549 | 0.87 | NR1H4 (0.65) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1484119 | 0.85 | NR1H4 (0.57) | NR1H4CYP2C9CYP3A4CYP2D6KCNH2 | |
| SCHEMBL12717886 | 0.84 | NR1H4 (0.55) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482788 | 0.80 | NR1H4 (0.50) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482952 | 0.79 | NR1H4 (0.51) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482521 | 0.79 | NR1H4 (0.49) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482540 | 0.78 | NR1H4 (0.50) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482630 | 0.78 | NR1H4 (0.49) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482570 | 0.77 | NR1H4 (0.48) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 | |
| SCHEMBL1482736 | 0.76 | NR1H4 (0.46) | NR1H4CYP2C9CYP3A4CYP2D6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | claimed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | claimed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | NR1H4 11/4885CYP2C9 2733/4885CYP3A4 1746/4885 |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885CYP2C9 62/4885CYP3A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.